Abstract
Metastatic prostate cancer remains a life-limiting disease; while we have seen significant advances in systemic approaches which form the backbone of management, no curative paradigm yet exists. Metastasis-directed therapy (MDT) with stereotactic ablative radiotherapy (SABR) has emerged as a promising complementary technique for the management of low-volume metastatic prostate cancer. Herein we will review the rationale, potential benefits, and practical considerations associated with this approach.
Original language | English (US) |
---|---|
Journal | Oncology (Williston Park, N.Y.) |
Volume | 33 |
Issue number | 10 |
State | Published - Oct 28 2019 |
ASJC Scopus subject areas
- Oncology
- Cancer Research